Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3061-3068

  Rubenstein, James L ^a   Hsi, Eric D ^b   Johnson, Jeffrey L ^c   Jung, Sin Ho ^c   Nakashima, Megan O ^b   Grant, Barbara ^d   Cheson, Bruce D ^e   Kaplan, Lawrence D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYTARABINE; DAPSONE; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PROTEIN BCL 6; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; TEMOZOLOMIDE; VALACICLOVIR; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; KERATOCONJUNCTIVITIS; MALE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCHOOL CHILD; THERAPY DELAY; YOUNG ADULT; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; MORTALITY; NONHODGKIN LYMPHOMA; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84884930066     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9957     Document Type: Article

References (40)

1. Batchelor T, Loeffler JS: Primary CNS lymphoma. J Clin Oncol 24:1281-1288, 2006 (Pubitemid 46622031)
2. Batchelor T, Carson K, O'Neill A, et al: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049, 2003 (Pubitemid 46594133)
3. Herrlinger U, Schabet M, Brugger W, et al: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent highdose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247-252, 2002 (Pubitemid 34111448)
4. DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002 (Pubitemid 36025280)
5. Abrey LE, DeAngelis LM, Yahalom J: Longterm survival in primary CNS lymphoma. J Clin Oncol 16:859-863, 1998 (Pubitemid 28108717)
6. Sun A, Bae K, Gore EM, et al: Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-smallcell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29:279-286, 2011
7. Ott RJ, Brada M, Flower MA, et al: Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27:1356-1361, 1991
8. Wong ET, Tishler R, Barron L, et al: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101: 139-145, 2004 (Pubitemid 38812433)
9. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80:B113-B117, 2001 (suppl 3)
10. Reni M, Zaja F, Mason W, et al: Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864-867, 2007 (Pubitemid 46452291)
11. Osoba D, Brada M, Yung WK, et al: Healthrelated quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36:1788-1795, 2000 (Pubitemid 30639499)
12. Osoba D, Brada M, Yung WK, et al: Healthrelated quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481-1491, 2000 (Pubitemid 30205394)
13. Soussain C, Suzan F, Hoang-Xuan K, et al: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742-749, 2001 (Pubitemid 32119089)
14. Ferreri AJ, Reni M, Foppoli M, et al: High-dose cytarabine plus high-dose methotrexate versus highdose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 374:1512-1520, 2009
15. Relling MV, Mahmoud HH, Pui CH, et al: Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 14:399-404, 1996 (Pubitemid 26051000)
16. Boehme V, Zeynalova S, Kloess M, et al: Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18:149-157, 2007 (Pubitemid 46152515)
17. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantlecell lymphoma: CALGB 59909. J Clin Oncol 27: 6101-6108, 2009
18. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005 (Pubitemid 46224010)
19. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
20. Ferreri AJ, Blay JY, Reni M, et al: Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272, 2003 (Pubitemid 46606155)
21. Abrey LE, Ben-Porat L, Panageas KS, et al: Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006 (Pubitemid 46631313)
22. Thiel E, Korfel A, Martus P, et al: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036-1047, 2010
23. Braaten KM, Betensky RA, de Leval L, et al: BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9:1063-1069, 2003 (Pubitemid 36329149)
24. Levy O, Deangelis LM, Filippa DA, et al: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 112:151-156, 2008
25. Chang CC, Kampalath B, Schultz C, et al: Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 127: 208-212, 2003 (Pubitemid 36231769)
26. Momota H, Narita Y, Maeshima AM, et al: Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. J Neurooncol 98:341-348, 2010
27. Kluk MJ, Chapuy B, Sinha P, et al: Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 7:e33813, 2012
28. Camilleri-Broët S, Crinie re E, Broët P, et al: A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases. Blood 107:190-196, 2006 (Pubitemid 43053543)
29. Hoang-Xuan K, Taillandier L, Chinot O, et al: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the European Organisation for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726-2731, 2003 (Pubitemid 46606318)
30. Angelov L, Doolittle ND, Kraemer DF, et al: Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: A multi-institutional experience. J Clin Oncol 27:3503-3509, 2009
31. Shah GD, Yahalom J, Correa DD, et al: Combined immunochemotherapy with reduced wholebrain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730-4735, 2007 (Pubitemid 350086474)
32. Wieduwilt MJ, Valles F, Issa S, et al: Immunochemotherapy with intensive consolidation for primary CNS lymphoma: A pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 18:1146-1155, 2012
33. Haldorsen IS, Espeland A, Larsen JL, et al: Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 44:728-734, 2005 (Pubitemid 41547074)
34. Hormigo A, Abrey L, Heinemann MH, et al: Ocular presentation of primary central nervous system lymphoma: Diagnosis and treatment. Br J Haematol 126:202-208, 2004 (Pubitemid 38961938)
35. Rubenstein JL, Fridlyand J, Shen A, et al: Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716-3723, 2006
36. Montesinos-Rongen M, Küppers R, Schlüter D, et al: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 155:2077-2086, 1999
37. Thompsett AR, Ellison DW, Stevenson FK, et al: V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94:1738-1746, 1999 (Pubitemid 29411324)
38. Winter JN, Weller EA, Horning SJ, et al: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 107:4207-4213, 2006 (Pubitemid 43801342)
39. Cerchietti LC, Ghetu AF, Zhu X, et al: A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17:400-411, 2010
40. Illerhaus G, Müller F, Feuerhake F, et al: High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147-148, 2008 (Pubitemid 351156168)